In the present study, the immunohistochemistry analysis of the examined sections revealed significantly higher expressions of GFAP in the EB-treated group, which indicated increased gliosis and reactivity of astrocytes against MS, supporting the idea of using GFAP as a biomarker for MS reported by [62–64]. This evidence concerns the gene GFAP and myeloid sarcoma.